Ziopharm's activist drama continues as another board member member resigns. Is the end in sight?

Max Gelman

Senior Editor

The very public and very bitter fight between Ziopharm Oncology and a minority activist investor continued Friday with the resignation of a board member …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ziopharm's activist drama continues as another board member member resigns. Is the end in sight?

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Zio­phar­m's ac­tivist dra­ma con­tin­ues as an­oth­er board mem­ber mem­ber re­signs. Is the end in sight?

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ziopharm's activist drama continues as another board member member resigns. Is the end in sight?